Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza

BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramuscular (i.m.) formulation of peramivir at the Options for the Control of Influenza Conference in Toronto, Ontario, Canada. This major international influenza conference is held only once every four years.

These studies represent an important component of the company's clinical development program for peramivir, a neuraminidase inhibitor being developed for the treatment of seasonal and potentially life-threatening influenza. Top-line data are summarized as follows:

    -- A total of 51 healthy adult volunteers received either one of three

       dose regimens of peramivir or placebo

    -- Maximum plasma concentrations of peramivir (ranging from approximately

       4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after

       administration

    -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours)

    -- The bioavailability of single doses of i.m. peramivir is high (>98%)

    -- Peramivir was well-tolerated in both of these studies

Jon P. Stonehouse, Chief Executive Officer of BioCryst said "these findings suggest an excellent safety profile of peramivir when given as an intramuscular injection, and, secondly, the concentrations of peramivir in blood after intramuscular dosing are reassuringly high and are similar to levels after intravenous administration. We look forward to the completion of our ongoing Phase II study of i.m. peramivir in the treatment of acute influenza in outpatients."

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on Janu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:8/28/2015)... , August 28, 2015 According ... by Tumor (Breast, Lung, Prostate) Type (Protein & Genetic ... Drug Discovery, Prognostic) & Geography - Global Forecast to ... expected to reach around 17,689.0 Million USD by 2020 ... of 2015 to 2020. Browse 191 ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
(Date:8/28/2015)... 28, 2015 Patterson Medical, formerly the ... PDCO ), is now an independent company with ... Patterson Medical by Madison Dearborn Partners (MDP).  ... for a transition period before rebranding as the ... medicine products.  With the focused resources and expertise ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 8, 2011 Johnson ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) ... Crucell. Reference is made to the joint press ... 8 December 2010 announcing the recommended cash offer by Johnson ...
... County Hospital is moving its computerization initiatives forward ... ChartAccess® Comprehensive EHR, the 20-bed hospital is planning ... requirements as stipulated under the American Recovery and ... same time, the Ness City, Kan.-based provider continues ...
Cached Medicine Technology:Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 2Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 3Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 4Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 5Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 6Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 7Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 2Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 3
(Date:8/30/2015)... ... , ... Certified Nutrition Businessman Reid Eckert agrees to extend his business relationship ... global sales and communications firm that offers U.S. brands a proven path to world ... Mr. Reid Eckert, as his interpretation of the nutritional needs of the human body ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who ... help the college expand its reach and impact through innovative technologies and strategies. , ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... consumers are good judges of affordability, but a new study ... by whether you think about a larger pool of resources ... cash in your wallet). Through a series of four ... food and time. Counting calories" Youre more likely to eat ...
... the University of California San Francisco has identified distinct ... is likely to develop subsequent invasive cancer after initial ... The research, published by Cell Press in the November ... be used to determine whether a woman should receive ...
... Shopko announced today the,appointment of W. Paul ... Officer. Jones will be responsible for the direction ... mass retailer. Jones, career has been highlighted ... mid-tier chain stores and big box retailers. He,has ...
... scientists,from around the world gathered for the 2007 ... The Symposium was,hosted by the Ringling Bros. and ... International Elephant Foundation (IEF), and was,held in conjunction ... Research. The Conference brought together experts in human ...
... releases nationwide eValue8,findings, SCOTTSDALE, Ariz., Nov. ... of health plan performance released today by ... health plans could do a,better job of ... in patient safety, care coordination, consumer selection ...
... Barry McMillen - Nicotine Cessation Expert and ... ... Using tobacco isn,t just a,habit; it,s an addiction. Hazelden has been ... years. The same principles,of the Hazelden treatment experience help tobacco users ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i...
... ophthalmic Nd: YAG laser YC-1600 is a ... superb versatility and clinical performance., ,Key Features, ... Lightweight Model ,Further weight reduction has ... in your office.,, Aiming Beam Rotation ...
... Given system, developed by Given Imaging of Israel, ... of a grape. Weighing in at only four ... 4 LED lights, battery and radio transmitter coated ... to digestive enzymes. Internal gastric images are transmitted ...
... pH Monitoring System is revolutionizing ... done. Bravo allows patients to ... activities during pH testing. And ... added convenience for patients allows ...
Medicine Products: